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Abstract
Background
Sponsors that seek to commercialize new drugs apply to the Food and Drug Administration
(FDA) which independently analyzes the raw data and reports the results on its website.
Objectives
This study sought to determine if there are differences between the FDA assessments and
journal reports on biologic agents developed for the treatment of rheumatoid arthritis.
Methods
Available data on FDA-approved drugs were extracted from the website, and a systematic
literature search was conducted to identify matching studies in peer-reviewed medical jour-
nals. Outcome measures were the American College of Rheumatology response criteria
ACR20 (efficacy) and withdrawal due to adverse events (safety). As effect size odds ratios
were estimated for each active trial arm vs. control arm (i.e. for both sources: FDA and jour-
nal report), followed by calculation of the ratios of the FDA and journal report odds ratios. A
ratio of odds ratios not equal to 1 was categorized as a discrepancy.
Results
FDA reports were available for 8 of 9 FDA-approved biologic agents for rheumatoid arthritis;
all identified trials (34) except one were published in peer-reviewed journals. Overall, dis-
crepancies were noted for 20 of the 33 evaluated trials. Differences in the apparent benefit
reporting were found in 39% (24/61) pairwise comparisons and in 11 cases these were sta-
tistically significant; the FDA report showed greater benefit than the journal publication in 15
PLOSONE | DOI:10.1371/journal.pone.0147556 January 25, 2016 1 / 13
OPEN ACCESS
Citation: Amarilyo G, Furst DE, Woo JMP, Li W,
Bliddal H, Christensen R, et al. (2016) Agreements
and Discrepancies between FDA Reports and
Journal Papers on Biologic Agents Approved for
Rheumatoid Arthritis: A Meta-Research Project. PLoS
ONE 11(1): e0147556. doi:10.1371/journal.
pone.0147556
Editor: Arvind Chopra, Center for Rheumatic
Diseases, INDIA
Received: October 6, 2015
Accepted: January 5, 2016
Published: January 25, 2016
Copyright: © 2016 Amarilyo et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The Parker Institute (HB, RC, and ST) is
supported by grants from the Oak Foundation.
Competing Interests: G. Amarilyo, consulting fees:
Novartis; Research grants: Novartis. S. Tarp,
Research grants paid to institute: AbbVie, Bristol-
Myers Squibb, Mundipharma, and Roche; Speakers
bureau: AstraZeneca, Pfizer, and Norpharma. R.
Christensen, Consulting fees paid to institute: Abbott/
comparisons and lesser benefit in 9. Differences in the reported harms were found in 51%
(28/55) pairwise comparisons and were statistically significant in 5. The “signal” in FDA
reports showed a less harmful effect than the journal publication in 17 comparisons whereas
a more harmful effect in 11. The differences were attributed to differences in analytic
approach, patient inclusion, rounding effect, and counting discrepancies. However, no dif-
ferences were categorized as critical.
Conclusion
There was no empirical evidence to suggest biased estimates between the two sources.
Increased and detailed transparency in publications would improve the understanding and
credibility of published results. Further, the FDA report was found to be a useful source
when data are missing in the published report (i.e. reporting bias).
Introduction
Randomized controlled trials (RCTs) are part of the development program of investigational
new drugs (INDs). They are usually conducted under the aegis of the sponsor (the pharmaceu-
tical company) and are intended to provide the sponsor with the relevant data to obtain
approval for marketing. In the USA, this is done by submitting a New Drug Application
(NDA) to the Federal Drug Administration (FDA) [1, 2]. The NDA includes the drug’s phar-
macokinetic/pharmacodynamic variables, the raw data set, copies of individual case report
forms of deaths, discontinuations and serious adverse events, and statistical analyses [1–3]. It is
reviewed by a panel of FDA experts (specialist physicians, statisticians, pharmacologists, and
toxicologists), each of whom prepares a written evaluation of the safety and efficacy of the
drug, followed by conclusions and recommendations.
After approval of the IND, the reviews are published on the FDA website (www.fda.gov)
[3,4]. In some cases, the FDA commissions an independent advisory committee to review the
findings. The hospitals and medical institutions that perform the clinical trials present the find-
ings at medical conferences and subsequently publish them in peer-reviewed medical journals
[3,5]. The medical community (incl. the Cochrane Collaboration) derives most of its knowl-
edge from the published trials.
It would be reasonable to expect that the data available from the FDA reports match the
results presented in the medical journals. However, studies of published premarketing trials
found significant publication biases for antidepressants and, to a lesser extent, antipsychotics
[6,7]. Others demonstrated that FDA findings of significant departures from good clinical
practice were seldom reflected in the peer-reviewed publication [8].
The recent exponential development of new molecular entities (NMEs) has posed a chal-
lenge for the FDA partly because it required the establishment of new regulations [3]. In the
field of rheumatology, the NMEs are most often biologic agents. To obtain approval to market
biologic agents, sponsors submit a Biologic License Application (BLA) to the FDA [9]. Like for
chemically synthesized drugs, the FDA analysis is presented on the website and the corre-
sponding clinical trial results are published in medical journals. However, although biologic
agents have revolutionized the treatment of several rheumatic diseases including rheumatoid
arthritis (RA) [10], no comparisons between the FDA and the published reports have been
done to date.
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Meta-research is the scientific discipline that aims to evaluate and improve research prac-
tices—including thematic areas of methods, reporting, reproducibility, evaluation, and incen-
tives [11]. The aim of the present study was to search for reporting biases and discrepancies
between the FDA and medical journal reports on biologic agents for RA.
Methods
No formal protocol is available for this current study. During the conduct of two related studies
(PROSPERO: CRD42014014842, CRD42013006702) the FDA reviews were found as useful
sources for data not published in the corresponding journal publication leading to the objective
of this study. A priori we defined the applied methods for comparing results in the FDA report
and the corresponding journal publications (S1 Material). The FDA-approved biologic agents
for RA tested in phase 2 and 3 trials were obtained from the FDA website in April 2015. We
then conducted a systematic search of three bibliographic databases through April 2015 to
identify matching journal publications: the Cochrane Central Register of Controlled Trials (the
Cochrane Library, latest issue), Medline, and EMBASE (S1 Table). The FDA reports and the
published trial reports were then reviewed for findings on the efficacy and safety of each drug.
Efficacy was evaluated using the American College of Rheumatology response criteria
(ACR20), which also served as the primary outcome measure in nearly all the RA trials. A posi-
tive ACR20 response translates into a reduction of at least 20% in the number of tender joints
and swollen joints plus an improvement of at least 20% in three or more of the following five
criteria: patient’s assessment of pain, patient’s assessment of disease activity, physician’s assess-
ment of disease activity, patient’s assessment of physical function, and erythrocyte sedimenta-
tion rate or serum C-reactive protein concentration [12]. Harmful events occurring during the
trial periods were evaluated by patient withdrawal due to adverse events (WdAEs) at the end of
the study.
Data collection and synthesis
The data extraction was performed by two reviewers (J.W. and W.L.) and reviewed by two oth-
ers (G.A. and S.T.). Both benefits and harms were extracted from both sources, and odds ratios
(ORs) were estimated for all active trial arms vs. control. The ORs of the FDA report and the
corresponding published paper were compared by calculating the ratio of ORs (ROR) for all
comparisons when the measure was reported in both sources, using the formula previously
described by Sterne et al. [13]: Exp{ln(OR[FDA])—ln(OR[Pub])} in Microsoft Excel. The antici-
pated correlation between the two lnORs was estimated empirically across all comparisons
(ACR20 r = 0.99; WdAE r = 0.93) and subsequently applied to estimate the corresponding vari-
ance of ROR as the OR measures are not mutually independent.
If a “discrepancy” was observed (ROR 6¼ 1), two of the authors (G.A. and S.T.) conducted a
thorough examination of the corresponding reports to determine the reason; disagreements
between the authors were adjudicated by a third author (D.E.F.). In the present study, all trials
are identified and coded by their FDA trial number.
Results
Data from 8 of the 9 FDA-approved biologic agents for RA were included in this study: abata-
cept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, and tocilizu-
mab. For the ninth, rituximab, the medical and statistical reviews of the randomized clinical
trials were missing from the FDA website, and we were unable to retrieve them even after
applying directly to the FDA. Fig 1 illustrates a flow diagram of the retrieved and excluded
Discrepancies between FDA Reports and Journal Papers on Biologic Agents for Rheumatoid Arthritis
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Fig 1. Flow diagram of retrieved and excluded randomized controlled trials. Legend: FDA = US Food and Drug Administration; RCT = randomized
controlled trials; WdAE = withdrawal due to adverse events; ACR20 = American College of Rheumatology response criteria 20.
doi:10.1371/journal.pone.0147556.g001
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articles. Overall 34 randomized controlled trials (2–6 trials per drug reviewed) were analyzed
by the FDA. All but one (anakinra 960182) were published in peer-reviewed journals (S2
Table).
Figs 2 and 3 shows the forest plots that represent the odds ratios for the ACR20 and the
WdAEs measures respectively on pairwise comparisons between biologics and placebo for
both the FDA review analysis data and peer reviewed publication data (analyzed data available
in S1 Data-Sheet).
Comparison of the benefit assessments
Of the 33 trials published in peer-reviewed journals, 4 were excluded from the ACR20 analysis
because pertinent data were missing from the FDA website (etanercept 160012), in the pub-
lished report (infliximab C0168T14), or from both the FDA website and the published report
(abatacept IM101031 and anakinra 990757). The 29 remaining trials yielded a total of 61 com-
parisons (several trials had a multiple trial-arm design) Fig 4. As summarized in Table 1 dis-
agreement was found in 24 (39%) of the 61 comparisons, including 11 in which the difference
was statistically significant (p<0.05) (S3 Table).
In 9 comparisons, the journal report showed greater efficacy than the FDA report, and in 15
comparisons, the FDA report showed better efficacy. As summarized in S4 Table, there were
several reasons for these discrepancies: i) Difference in analytic approach (9 comparisons)–one
source used the ITT population whereas the other used the modified ITT; ii) Difference in
patient included in the analysis (6 comparisons)—the FDA report excluded patients from dis-
barred sites (adalimumab SE09 and DE31) or patients who were missing ACR20 assessments.
For example, in the certolizumab trial (27), subjects with no ACR20 data were included in the
denominator in the published report but not in the FDA report. When the FDA conducted a
further calculation using the non-responder imputation method, as in the published study, the
results were similar in both reports; iii) Rounding effect (6 comparisons)—the published report
described the data in percent whereas the FDA report described the data by number of
responders; iv) Counting discrepancies (3 comparisons)–The FDA and published reports dif-
fered in the number of patients analyzed or number of patients with a particular finding. In
comparisons included in this category, we could not find a reasonable explanation for the
discrepancy.
Comparison of harm assessments
Of the 33 trials published in peer-reviewed journals, 7 were excluded from the WdAEs analysis
because pertinent data were missing from the FDA reports (etanercept 160004; etanercept
160012; abatacept IM101101, tocilizumab WA17823) or the published report (golimumab
C0524T05, C0524T06 and C0524T11). The 26 remaining trials yielded a total of 55 compari-
sons Fig 5. As summarized in Table 1 disagreement was found in 28 of the 55 comparisons
including 5 in which the difference was statistically significant (p<0.05) (S4 Table).
In 11 comparisons, the journal report showed higher safety (lower WdAE estimates) than
the FDA report, and in 17 comparisons, the FDA report showed higher safety than the journal
report. As summarized in S3 Table, 20 discrepancies were attributed to counting differences
(no clear explanation). The other reasons were differences in patient inclusion (6 comparisons)
and in analytic approach (2 comparisons).
Discussion
The present study compared the data on new biologic drugs for RA published on the FDA web-
site and in peer-reviewed medical journals. In addition to thorough and independent analysis
Discrepancies between FDA Reports and Journal Papers on Biologic Agents for Rheumatoid Arthritis
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Fig 2. Forest plots representing the odds ratios for the ACR20measure of the FDA review report and
the journal publication. Legend: 95%CI = 95% confidence interval; Solid circles = FDA report; open
circles = journal publication; ACR20 = American College of Rheumatology response criteria 20. Circles
without confidence interval indicate outcome was not reported.
doi:10.1371/journal.pone.0147556.g002
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Fig 3. Forest plots representing the odds ratios for withdrawal due to adverse events of the FDA
report and peer reviewed publication. Legend: 95%CI = 95% confidence interval; Solid circles = FDA
report; open circles = journal publication. Circles without confidence interval indicate outcome was not
reported.
doi:10.1371/journal.pone.0147556.g003
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Fig 4. Forest plots representing the ratio of odds ratios for the ACR20measure between FDA review
analysis data and peer reviewed publication data. Legend: ACR20 = American College of Rheumatology
response criteria 20; 95%CI = 95% confidence interval. Diamonds without confidence interval indicate
outcome was not reported in one or both sources.
doi:10.1371/journal.pone.0147556.g004
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of raw data from RCT's, the FDA reviews offer a unique source of information when preform-
ing meta-analysis for missing data in the journal publication. Discrepancies in outcome were
noted in a substantial proportion of pairwise comparisons in terms of benefit measures
(ACR20 responses, 39%) and harms (WdAEs, 51%). However, closer inspection revealed that
many of the discrepancies in the ACR20 measure were caused merely by rounding effects or
inclusion/ exclusion of patients from the analysis. Moreover, in 63% of the pairwise compari-
sons, the FDA analysis favored the test medication relative to the peer-reviewed publication,
which weighs strongly against reporting bias toward positive efficacy outcomes.
For WdAEs, conclusions regarding differences between the sources and reporting bias were
more complex. In almost half the comparisons with discrepant findings (11/28), the published
reports showed higher safety than the FDA reports. However, 9 of the differences were
explained by counting discrepancies, i.e., we could not find a reasonable explanation for them,
and only one-third were statistically significant. Usually, there were differences of 1–2 patients
between the FDA and the journal reports, but in some cases, the counting discrepancies were
larger. For example, in the anakinra 560 trial, major discrepancies were found in all arms: for
anakinra 30 mg, the FDA reported 19 events and the published study, 6 events; for anakinra 75
mg, 18 and 8 events, respectively; for anakinra 150 mg, 20 and 13 events, respectively; and for
placebo, 24 and 6 events, respectively. This raises the question of reporting bias toward more
favorable safety results, particularly because the counting discrepancies could not be explained
(which was true even for anakinra). On the other hand, in 61% of the discrepancies, fewer
WdAEs were found in the FDA analyses, indicating no such bias.
Table 1. Summary of discrepancies between FDA and peer-reviewed journal reports.
Drug No. of analyzed RCTs No. of analyzed arms (vs. placebo) Matched Favors FDA Favors publication
ACR20
Abatacept 5 8 7 1 -
Adalimumab 4 10 6 4 -
Anakinra 3 9 5 3 1
Certolizumab 4 6 1 - 5
Etanercept 4 8 8 - -
Golimumab 3 8 5 3 -
Inﬂiximab 1 4 - 1 3
Tocilizumab 5 8 5 3 -
Total 29 61 (100%) 37 (61%) 15 (24%) 9 (15%)
WdAEs
Abatacept 5 8 6 1 1
Adalimumab 4 10 6 4 -
Anakinra 4 10 5 3 2
Certolizumab 4 6 2 4 -
Etanercept 3 5 3 1 1
Golimumab - - - - -
Inﬂiximab 2 10 5 4 1
Tocilizumab 4 6 - - 6
Total 26 55 (100%) 27 (49%) 17 (31%) 11 (20%)
RCT = randomized controlled trial, No. = number of patients, ACR20 = American College of Rheumatology 20, WdAEs = withdrawal of patients due to
adverse events, FDA = Food and Drug Administration.
doi:10.1371/journal.pone.0147556.t001
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Fig 5. Forest plots representing the ratio of odds ratios for theWdAEmeasure on pairwise
comparisons between FDA review analysis data and peer reviewed publication data. Legend:
WdAE = withdrawal due to adverse events; 95%CI = 95% confidence interval. Diamonds without confidence
interval indicate outcome was not reported in one or both sources.
doi:10.1371/journal.pone.0147556.g005
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In some instances, the analytic approach differed between the FDA and the published
reports, mainly because one analysis used a strict ITT population and other datasets were
based on a modified ITT (e.g., treated) population. It is noteworthy that the FDA itself was not
consistent in its preference for one or the other approach among the analyzed trials. Indeed, in
some trials, a modified ITT analysis was done first, followed by additional analyses for the pri-
mary endpoint using the strict ITT subset with a non-responder imputation for missing data.
The FDA has written guidelines but not overly rigid requirements for the design or conduct of
clinical trials and the specific data that must be collected [14]. We believe requiring transpar-
ency, consistency, and detailed completeness in study analyses would help to minimize discrep-
ancies of this type and avoid bias.
Unlike similar studies in other fields of medicine [6,7,15], the discrepancies between the
FDA and the published reports for the outcome measures evaluated were not sufficiently large
to change the main efficacy and safety conclusions of the trial. However, we believe that after
its summaries are made available to the public, the FDA could notify authors of the trial studies
about discrepancies in the results. This would encourage authors to review their data and lead
to greater transparency and consistency in the analyses.
Finally, trials that are conducted but not published are a matter of concern, especially if they
report negative results and/or do not achieve their primary outcomes. Indeed, one low-dose
(2.5, 10, 30 mg/day) short-term (12 week) anakinra monotherapy trial (no. 960182) that was
included in the BLA along with its open-label extension (no. 970102) were never published. In
this study, there was no significant difference in ACR20 response or other efficacy endpoint
between any of the anakinra arms and placebo at 12 weeks. On further examination to deter-
mine if these results were due to baseline covariates, subject/disease characteristics, or potential
safety issues, no explanation for the lack of effect was found [16]. According to the FDA Arthri-
tis Drugs Advisory Committee Briefing Package Report for Anakinra, the unpublished study
provided support for utilization of a higher dose of anakinra in the treatment of subjects with
RA [16].
Our study has two main limitations. First, we did not include FDA-approved rituximab
because no review (medical or statistical) was available on the FDA website, and we were
unable to access the data even after applying directly to the FDA authorities. Second, we exam-
ined a single efficacy measure and a single safety measure. These were used mainly because
they were the outcome measures that were common to most of the studies and could therefore
be analyzed across studies.
In conclusion, pairwise comparisons and FDA reviews of new biologic agents for RA and
the corresponding published clinical trials show a discrepancy in efficacy in about one-half of
cases and in safety in about one-third of cases. Many factors may account for these differences.
Although some of the differences were statistically significant, they did not affect the overall
conclusions. Importantly, given that the medical community tends to derive most of its knowl-
edge from peer-reviewed journals, there was no empirical evidence to suggest reporting bias.
Increased detailed description and transparency in publications would increase the credibility
of published results. Further, the FDA report was found to be a useful source when data are
missing in the published report (i.e. reporting bias).
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